Aldevron, a leading global provider of high-quality plasmid DNA, mRNA and recombinant proteins used in vaccines, gene and cell therapy, gene editing and diagnostic applications, is being sold by EQT to Danaher Corporations for an enterprise value of USD 9.6 billion. Headquartered in Fargo, North Dakota, Aldevron provides custom manufacturing capabilities for the development and supply of new breakthrough genetic medicine, and has been key in the fight against COVID-19 through its supply of plasmid DNA used in mRNA vaccines.
After acquiring a majority interest in Aldevron in 2019, EQT has supported its long-term growth and investments. A new 189,000 sq ft facility has also recently been constructed and validated, supplementing Aldevron’s GMP manufacturing capacity.
“Genetic medicine is the future and our field is expanding rapidly. EQT has been a great partner to us and played an important role in supporting our company as we scale. Danaher is an excellent strategic fit and new home for Aldevron, and we look forward to working with them,” said Kevin Ballinger, CEO of Aldevron.
Eric Liu, Partner and Global Co-Head of Healthcare at EQT, added, “Aldevron is integral to the development and supply of new types of therapies that address previously uncurable medical conditions. We are proud to have supported Aldevron and its mission to deliver the highest quality products that help improve patient lives across the world.”
(Source: Cision, 17 th June 2021)